Pilot study of the use of Yin Qiao San in children with conventional antipyretic hypersensitivity
10.5415/apallergy.2015.5.4.222
- Author:
Woei Kang LIEW
1
;
Wenyin LOH
;
Wen Chin CHIANG
;
Anne GOH
;
Oh Moh CHAY
;
Mona IANCOVICI KIDON
Author Information
1. Department of Paediatric Medicine, Allergy Service, KK Women's and Children's Hospital, Singapore 229899, Singapore. loh.wenyin@singhealth.com.sg
- Publication Type:Clinical Trial
- Keywords:
Child;
Cyclooxygenase 1;
Herbal Medicine;
Hypersensitivity;
Anti-Inflammatory Agents, Non-Steroidal;
Acetaminophen
- MeSH:
Acetaminophen;
Anti-Inflammatory Agents, Non-Steroidal;
Antipyretics;
Asian Continental Ancestry Group;
Child;
Cyclooxygenase 1;
Diagnosis;
Eating;
Fever;
Herbal Medicine;
Humans;
Hypersensitivity;
Ibuprofen;
Pilot Projects;
Prospective Studies;
Urticaria
- From:
Asia Pacific Allergy
2015;5(4):222-229
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Children with a diagnosis of cross-reactive hypersensitivity to both paracetamol and nonsteroidal anti-inflammatory drugs are limited in their choice of antipyretics. OBJECTIVE: The aim of this pilot study is to evaluate the feasibility of using a Chinese proprietary medicine, Yin Qiao San (YQS), for fever relief. METHODS: A single centre, open label, prospective clinical trial exploring the tolerability and feasibility of using YQS for fever relief in children who are unable to use conventional antipyretic medications. Children between 1-18 years of age with hypersensitivity to multiple antipyretics were recruited. Eligible participants underwent an oral provocation test with YQS. Children who passed the oral provocation test were instructed to take a prescribed dose of YQS when the temperature was >38.0℃ and continued till the fever settled. Time taken for fever resolution and any adverse events were collected. RESULTS: A total of 21 children, mean age 10.7 years, had a diagnosis of paracetamol and ibuprofen hypersensitivity. All except one patient successfully tolerated an oral challenge of YQS. Of the 88 doses of YQS taken for fever over 38.0℃, 16 (18%) had documented temperature reduction 2 hours after ingestion and 30 (34%) had documented temperature reduction 4 hours after ingestion. There were 2 reports of urticaria after YQS use which were attributed to flare of recurrent spontaneous urticaria during the illness. None of the patients developed symptoms of circulatory compromise or respiratory distress. CONCLUSION: YQS is generally well tolerated in patients with paracetamol and ibuprofen hypersensitivity.
